Citius Pharmaceuticals Inc (NASDAQ:CTXR) collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company,…
I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients
University of Pittsburgh dose-ranging study expected to begin in the fourth quarter of 2022
Collaboration marks second